Yakult initiates phase I trial in multiple myeloma with perifosine in Japan

Friday, June 29, 2012 12:12 PM

Aeterna Zentaris’ Japanese partner Yakult Honsha has initiated a phase I trial in multiple myeloma with perifosine, the company's oral Akt/PI3K inhibitor drug.

Yakult, who is sponsoring and conducting the trial in Japan, reported that the first patient has been dosed with perifosine.

The open-label, two step phase I trial in which perifosine is combined with bortezomib (Velcade) and dexamethasone in patients with refractory multiple myeloma who have previously been treated with bortezomib. The trial is expected to include a total of 18 patients (6 in step one and 12 in step two). Patients will receive perifosine daily (50mg, Days 1-21) in combination with  bortezomib (1.3 mg/m, Days 1, 4, 8 and 11) and dexamethasone (20mg, Days 1, 2, 4, 5, 8, 9,

 11 and 12) according to a three-week cycle (21 days ± 3 days). The primary endpoint is safety while secondary endpoints include response rate, progression-free survival, and time to tumor progression.

"We would like to thank our partner Yakult for their close collaboration in initiating this important phase I trial in multiple myeloma which is necessary at this time in order to comply with Japan's specific registration requirements,” said Juergen Engel, PhD, president and CEO of Aeterna Zentaris. “Perifosine [is] also currently in a phase III trial in other parts of the world in multiple myeloma—for which we expect to reach an interim analysis in the first quarter of next year."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

October 20

Toronto Star, with FDA data, exposes weaknesses in Health Canada's clinical trial, inspection oversight

Crowdsourcing effort aims to fund updated online social media guide for sponsor interaction with patients

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs